Your browser is no longer supported. Please, upgrade your browser.
Settings
PLXP PLx Pharma Inc. daily Stock Chart
PLXP [NASD]
PLx Pharma Inc.
Index- P/E- EPS (ttm)-1.14 Insider Own5.73% Shs Outstand8.58M Perf Week-3.55%
Market Cap48.91M Forward P/E- EPS next Y-0.98 Insider Trans- Shs Float8.25M Perf Month14.46%
Income-9.90M PEG- EPS next Q-0.37 Inst Own24.30% Short Float1.63% Perf Quarter153.38%
Sales0.80M P/S61.13 EPS this Y-1570.00% Inst Trans-2.07% Short Ratio2.40 Perf Half Y31.03%
Book/sh0.39 P/B14.62 EPS next Y33.30% ROA-42.20% Target Price10.50 Perf Year-8.80%
Cash/sh1.92 P/C2.96 EPS next 5Y40.00% ROE-168.50% 52W Range1.00 - 6.44 Perf YTD272.55%
Dividend- P/FCF- EPS past 5Y- ROI-95.30% 52W High-11.48% Beta5.37
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low470.00% ATR0.47
Employees11 Current Ratio4.80 Sales Q/Q100.00% Oper. Margin- RSI (14)58.87 Volatility7.35% 9.11%
OptionableNo Debt/Eq2.12 EPS Q/Q10.20% Profit Margin- Rel Volume0.60 Prev Close5.93
ShortableYes LT Debt/Eq1.53 EarningsMar 08 BMO Payout- Avg Volume55.94K Price5.70
Recom2.50 SMA207.75% SMA5012.32% SMA20040.92% Volume33,322 Change-3.88%
Jan-14-19Downgrade Raymond James Outperform → Mkt Perform
Mar-13-19 01:14AM  Edited Transcript of PLXP earnings conference call or presentation 8-Mar-19 1:30pm GMT Thomson Reuters StreetEvents +5.97%
Mar-08-19 06:50AM  PLx Pharma Inc. Reports Fourth Quarter 2018 Results GlobeNewswire
Feb-25-19 04:30PM  PLx Pharma Inc. to Discuss 2018 Fourth Quarter and Full Year Financial Results on March 8, 2019 Conference Call GlobeNewswire
Feb-20-19 04:55PM  PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing GlobeNewswire
Feb-14-19 11:30AM  PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders GlobeNewswire
Jan-17-19 09:55AM  PLx Pharma's Capital Raise More Dilutive Than Expected, Raymond James Says Benzinga
Dec-20-18 07:32PM  PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing GlobeNewswire -24.43%
Dec-18-18 04:30PM  PLx Pharma Inc. to Present at Biotech Showcase 2019 GlobeNewswire -6.92%
Nov-19-18 09:31AM  Edited Transcript of PLXP earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 06:50AM  PLx Pharma Inc. Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 07:00AM  PLx Pharma Inc. to Discuss 2018 Third Quarter Financial Results on November 9, 2018 Conference Call GlobeNewswire
Oct-01-18 08:57AM  Who Really Owns PLx Pharma Inc (NASDAQ:PLXP)? Simply Wall St.
Sep-10-18 04:30PM  PLx Pharma Inc. to Present at Janney Healthcare Conference on September 18 GlobeNewswire
Aug-10-18 07:00AM  PLx Pharma Inc. Reports Second Quarter 2018 Results GlobeNewswire
Jun-11-18 04:30PM  PLx Pharma Inc. to Present at JMP Securities Life Sciences Conference GlobeNewswire
May-11-18 06:50AM  PLx Pharma Inc. Reports First Quarter 2018 Results GlobeNewswire
Apr-24-18 07:50AM  Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure ACCESSWIRE -8.14%
Mar-23-18 06:50AM  PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results GlobeNewswire -16.94%
Mar-15-18 04:30PM  PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call GlobeNewswire
Nov-21-17 07:29PM  Is PLx Pharma Incs (PLXP) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-10-17 06:00AM  PLx Pharma, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-17 06:56PM  PLx Pharma reports 3Q loss Associated Press
PLx Pharma Inc., a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system, including PL1200 Ibuprofen 200 mg, a clinical-stage GI-safer ibuprofen product for pain and inflammation. The company was founded in 2002 and is headquartered in Houston, Texas.